Daewoong Pharmaceutical said that it has launched its botulinum toxin (BTX) product, Nuceiva, in Canada. Nuceiva is also known as Jeuveau in the U.S. and Nabota in Korea.
|Daewoong headquarters in Samsung-dong, southern Seoul.|
Evolus, Daewoong's exclusive partner for BTX, had obtained sales approval for Nuceiva from Health Canada in August last year.
Canada is a member country of seven major developed countries (G7) and the fifth member to join the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), after the U.S., EU, Japan, and Switzerland.
Clarion Medical, Evlous' Candian partner, will handle sales for Nuceiva.
The company is a large medical equipment manufacturer headquartered in Ontario with a strong network in the local cosmetic surgery market.
"Like the U.S., Canada has only three existing botulinum toxin preparations which have been on the market for more than a decade," said Park Sung-soo, head of Daewoong's Nabota business division. "The company expects rapid growth in North America, a developed market for pharmaceuticals, based on the superior quality of our new products and our strong network of local partners."
<© Korea Biomedical Review, All rights reserved.>